476 related articles for article (PubMed ID: 29657088)
21. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].
Latteux G; Lebdai S; Hoarau N; Abadie-Lacourtoisie S; Delva R; Chautard D; Azzouzi AR; Bigot P
Prog Urol; 2013 Mar; 23(3):184-94. PubMed ID: 23446283
[TBL] [Abstract][Full Text] [Related]
23. Monocarboxylate transporter 1 is an independent prognostic factor in esophageal squamous cell carcinoma.
Chen X; Chen X; Liu F; Yuan Q; Zhang K; Zhou W; Guan S; Wang Y; Mi S; Cheng Y
Oncol Rep; 2019 Apr; 41(4):2529-2539. PubMed ID: 30720131
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
Haas NB; Manola J; Dutcher JP; Flaherty KT; Uzzo RG; Atkins MB; DiPaola RS; Choueiri TK
JAMA Oncol; 2017 Sep; 3(9):1249-1252. PubMed ID: 28278333
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical evaluation and prognostic value of monocarboxylate transporter 1 (MCT1) and 4 (MCT4) in T-cell non-Hodgkin lymphoma.
Zhao H; Chen Y; Liao YP; Chen HM; Yang QH; Xiao Y; Luo J; Chen ZZ; Yi L; Hu GY
Clin Exp Med; 2023 Feb; 23(1):55-64. PubMed ID: 35239073
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
27. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Barbastefano J; Garcia JA; Elson P; Wood LS; Lane BR; Dreicer R; Campbell SC; Rini BI
BJU Int; 2010 Nov; 106(9):1266-9. PubMed ID: 20346042
[TBL] [Abstract][Full Text] [Related]
28. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
Busch J; Seidel C; Kempkensteffen C; Johannsen M; Wolff I; Hinz S; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2011 Dec; 60(6):1163-70. PubMed ID: 21802830
[TBL] [Abstract][Full Text] [Related]
29. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
Doyen J; Trastour C; Ettore F; Peyrottes I; Toussant N; Gal J; Ilc K; Roux D; Parks SK; Ferrero JM; Pouysségur J
Biochem Biophys Res Commun; 2014 Aug; 451(1):54-61. PubMed ID: 25058459
[TBL] [Abstract][Full Text] [Related]
30. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
[TBL] [Abstract][Full Text] [Related]
31. Clinically relevant HIF-1α-dependent metabolic reprogramming in oropharyngeal squamous cell carcinomas includes coordinated activation of CAIX and the miR-210/ISCU signaling axis, but not MCT1 and MCT4 upregulation.
Sáenz-de-Santa-María I; Bernardo-Castiñeira C; Secades P; Bernaldo-de-Quirós S; Rodrigo JP; Astudillo A; Chiara MD
Oncotarget; 2017 Feb; 8(8):13730-13746. PubMed ID: 28099149
[TBL] [Abstract][Full Text] [Related]
32. Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma.
Nouhaud FX; Pfister C; Defortescu G; Giwerc A; Charbit D; Gouerant S; Sabourin JC; Di Fiore F
Anticancer Drugs; 2015 Sep; 26(8):866-71. PubMed ID: 26020808
[TBL] [Abstract][Full Text] [Related]
33. MCT1 expression is independently related to shorter cancer-specific survival in clear cell renal cell carcinoma.
de Carvalho PA; Bonatelli M; Cordeiro MD; Coelho RF; Reis S; Srougi M; Nahas WC; Pinheiro C; Leite KRM
Carcinogenesis; 2021 Dec; 42(12):1420-1427. PubMed ID: 34668521
[TBL] [Abstract][Full Text] [Related]
34. Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer.
Boers-Sonderen MJ; Desar IM; Fütterer JJ; Mulder SF; De Geus-Oei LF; Mulders PF; Van Der Graaf WT; Oyen WJ; Van Herpen CM
Anticancer Res; 2015 Oct; 35(10):5601-6. PubMed ID: 26408732
[TBL] [Abstract][Full Text] [Related]
35. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
[TBL] [Abstract][Full Text] [Related]
36. Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy.
Mai HX; Mei GH; Zhao FL; Li BT; Tang YY; Zhang B; Xu XJ; Chen LJ
J Cancer Res Ther; 2018 Jun; 14(Supplement):S427-S432. PubMed ID: 29970701
[TBL] [Abstract][Full Text] [Related]
37. Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma.
Pinheiro C; Albergaria A; Paredes J; Sousa B; Dufloth R; Vieira D; Schmitt F; Baltazar F
Histopathology; 2010 Jun; 56(7):860-7. PubMed ID: 20636790
[TBL] [Abstract][Full Text] [Related]
38. Monocarboxylate Transporters MCT1 and MCT4 Regulate Migration and Invasion of Pancreatic Ductal Adenocarcinoma Cells.
Kong SC; Nøhr-Nielsen A; Zeeberg K; Reshkin SJ; Hoffmann EK; Novak I; Pedersen SF
Pancreas; 2016 Aug; 45(7):1036-47. PubMed ID: 26765963
[TBL] [Abstract][Full Text] [Related]
39. A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
Stubbs C; Bardoli AD; Afshar M; Pirrie S; Miscoria M; Wheeley I; Porfiri E
Anticancer Res; 2017 Jan; 37(1):253-259. PubMed ID: 28011500
[TBL] [Abstract][Full Text] [Related]
40. Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Pilskog M; Bostad L; Edelmann RJ; Akslen LA; Beisland C; Straume O
J Pathol Clin Res; 2018 Apr; 4(2):114-123. PubMed ID: 29665322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]